文献速递胸部肿瘤放疗

中心型早期非小细胞肺癌的SBRT:何为「过于中心」?

SBRT for centrally localized NSCLC - What is too central?
PubMed 文献 · Radiat Oncol · 2016-12-03

多数中心使用PTV 48-60 Gy/8次、最大剂量125-150%;小肿瘤且距主支气管≥2 cm时超85%中心认为有SBRT指征,而7 cm累及隆突肿瘤仅1个中心选择SBRT。

要点

  • 多数中心采用48-60 Gy/8次、最大剂量125-150%的处方模式。
  • 肿瘤小且距主支气管≥2 cm时,超85%中心认为有SBRT指征。
  • 全肺切除史或紧邻肺门/纵隔结构不被视为SBRT禁忌。

核心结论

  • 在DEGRO立体定向放疗工作组内,小(<4 cm)早期NSCLC且距主支气管至少2 cm时SBRT是常见指征。
  • 更大和更中心位置肿瘤的治疗争议有待正在进行的前瞻性临床试验解决。

研究设计与样本

  • 在DEGRO立体定向放疗工作组年会上发放两部分问卷,代表德国和瑞士的中心参与。
  • 第二部分以9例原发NSCLC患者的病例为例,展示增强CT和PET影像,专门评估中心型肺肿瘤SBRT实践。

主要发现

  • 9例患者中有3例肿瘤小且距主支气管不近于2 cm,超85%中心认为有明确SBRT指征。
  • 肿瘤直径超过4 cm或距隆突近于4 cm时,50-80%中心认为有SBRT指征。
  • 1例7 cm肿瘤累及隆突,仅1个中心会选择SBRT治疗。

关键数值与推荐

  • 多数中心使用的分次方案为PTV处方剂量48-60 Gy分8次,最大剂量125-150%。
  • 小肿瘤且距主支气管至少2 cm时,超85%中心认为有SBRT指征。
  • 全肺切除史或紧邻肺门/纵隔结构不被视为SBRT禁忌证。
  • 肿瘤超过4 cm或距隆突近于4 cm时,50-80%中心认为有SBRT指征。

临床怎么用

  • 对早期小NSCLC且距主支气管至少2 cm者,可考虑SBRT为常见指征。
  • 全肺切除史或肿瘤紧邻肺门/纵隔结构不应作为SBRT的绝对禁忌。
  • 对直径超过4 cm或距隆突近于4 cm的中心型肿瘤,SBRT决策需谨慎并期待前瞻性试验证据。

局限性

  • 结果为DEGRO工作组年会参与中心的问卷调查,仅代表德国和瑞士部分中心实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current guidelines recommend stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) in medically inoperable patients. There are excellent outcome and toxicity data for SBRT of peripheral lung tumors. However, the discussion on SBRT for centrally located tumors is controversial. This study evaluated current clinical practice regarding SBRT of centrally located lung tumors, to identify common fractionation schedules and commonly accepted contraindications for SBRT. METHODS: A questionnaire consisting of two parts was introduced at the annual meeting of the DEGRO working group on stereotactic radiotherapy, representing centers in Germany and Switzerland. The first part of the questionnaire covered general information about the centers, whereas the second part specifically addressed SBRT of centrally located lung tumors, using case examples of nine primary NSCLC patients. Reconstructions of a contrast enhanced CT, as well as PET-Imaging for each case were demonstrated to the participants. RESULTS: Twenty-six centers participated in the meeting. The majority was academic (73%), participated in interdisciplinary thoracic oncology tumorboards (88%) and offered SBRT for lung tumors (96%). Two centers questioned the indication of SBRT for central lung tumors because of lack of evidence. The majority of centers had experience in SBRT for central lung tumors (88%) and half of the centers reported more than ten cases treated during a median period of five years. Most fractionation schedules used PTV encompassing doses of 48-60 Gy in eight fractions with maximum doses of 125-150%. A clear indication for SBRT treatment was seen by more than 85% of centers in three of the nine patients in whom tumors were small and not closer than 2 cm to the main bronchus. Prior pneumonectomy or immediate adjacency to hilar/mediastinal structures were not considered as contraindications for SBRT. In cases where the tumor exceeded 4 cm in diameter or was located closer than 4 cm to the carina 50-80% of centers saw an indication for SBRT. One case, with a 7 cm tumor reaching to the carina would have been treated with SBRT only by one center. CONCLUSION: Within DEGRO working group on stereotactic radiotherapy, SBRT for small (<4 cm) early stage NSCLC is a common indication, if the minimal distance to the main bronchi is at least 2 cm. The controversy on the treatment of larger and more central tumors will hopefully be solved by ongoing prospective clinical trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Roesch J, Panje C, Sterzing F, et al. SBRT for centrally localized NSCLC - What is too central? Radiat Oncol. 2016. PMID: 27912764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。